Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,286,879
  • Shares Outstanding, K 127,830
  • Annual Sales, $ 1,004 M
  • Annual Income, $ 22,390 K
  • EBIT $ 55 M
  • EBITDA $ 59 M
  • 60-Month Beta 0.26
  • Price/Sales 2.40
  • Price/Cash Flow 90.05
  • Price/Book 6.43

Options Overview Details

View History
  • Implied Volatility 54.22% (+2.84%)
  • Historical Volatility 34.44%
  • IV Percentile 22%
  • IV Rank 30.53%
  • IV High 97.27% on 07/28/25
  • IV Low 35.30% on 03/16/26
  • Expected Move (DTE 28) 1.79 (9.93%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 88
  • Volume Avg (30-Day) 246
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 22,962
  • Open Int (30-Day) 21,839
  • Expected Range 16.19 to 19.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.38
  • Number of Estimates 12
  • High Estimate -0.17
  • Low Estimate -0.62
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +48.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.43 +3.07%
on 03/18/26
22.81 -21.22%
on 02/20/26
-4.83 (-21.18%)
since 02/19/26
3-Month
17.43 +3.07%
on 03/18/26
27.46 -34.56%
on 01/09/26
-6.68 (-27.10%)
since 12/19/25
52-Week
16.10 +11.61%
on 05/15/25
30.48 -41.04%
on 10/28/25
-6.84 (-27.57%)
since 03/19/25

Most Recent Stories

More News
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March...

APLS : 17.97 (+0.45%)
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Full-year 2025 net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI ® (pegcetacoplan) full year 2025...

APLS : 17.97 (+0.45%)
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual...

APLS : 17.97 (+0.45%)
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ®   (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE...

APLS : 17.97 (+0.45%)
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...

APLS : 17.97 (+0.45%)
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

NEW YORK , Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:

CADE : 42.11 (-1.66%)
HBAN : 15.17 (+0.40%)
CIVI : 27.38 (-1.37%)
RYN : 19.90 (-1.58%)
APLS : 17.97 (+0.45%)
AHR : 51.12 (-2.76%)
BROS : 50.93 (-0.49%)
AMRX : 12.34 (-0.40%)
LZ : 6.16 (-1.60%)
AEIS : 327.80 (+2.56%)
FITB : 43.66 (-0.55%)
PCH : 41.73 (+0.05%)
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Full-year 2025 preliminary 1 U.S. net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled...

APLS : 17.97 (+0.45%)
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44 th Annual J.P. Morgan Healthcare Conference on...

APLS : 17.97 (+0.45%)
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent...

APLS : 17.97 (+0.45%)
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:...

APLS : 17.97 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 18.57
2nd Resistance Point 18.29
1st Resistance Point 18.13
Last Price 17.97
1st Support Level 17.69
2nd Support Level 17.41
3rd Support Level 17.25

See More

52-Week High 30.48
Fibonacci 61.8% 24.99
Fibonacci 50% 23.29
Fibonacci 38.2% 21.59
Last Price 17.97
52-Week Low 16.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar